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Abstract
The natural microenvironment of tumors is composed of extracellular matrix (ECM), blood 
vasculature, and supporting stromal cells. The physical characteristics of ECM as well as the 
cellular components play a vital role in controlling cancer cell proliferation, apoptosis, 
metabolism, and differentiation. To mimic the tumor microenvironment outside the human body 
for drug testing, two-dimensional (2-D) and murine tumor models are routinely used. Although 
these conventional approaches are employed in preclinical studies, they still present challenges. 
For example, murine tumor models are expensive and difficult to adopt for routine drug screening. 
On the other hand, 2-D in vitro models are simple to perform, but they do not recapitulate natural 
tumor microenvironment, because they do not capture important three-dimensional (3-D) cell–cell, 
cell–matrix signaling pathways, and multi-cellular heterogeneous components of the tumor 
microenvironment such as stromal and immune cells. The three-dimensional (3-D) in vitro tumor 
models aim to closely mimic cancer microenvironments and have emerged as an alternative to 
routinely used methods for drug screening. Herein, we review recent advances in 3-D tumor model 
generation and highlight directions for future applications in drug testing.
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Introduction
Tumor growth and aggressiveness are influenced by the microenvironment surrounding the 
tumor mass [1–5]. The native tumor microenvironment is composed of extracellular matrix 
(ECM), cell–cell contact, and cell–matrix interactions [6–8]. The ECM consists of a 
nanofibrous mesh of proteins (i.e., elastin, collagen, fibronectin, and laminin), which fill the 
extracellular spaces around the cells to help them stay connected with each other by 
adhesion proteins [9]. In addition, the ECM components are involved in various cell 
signaling pathways [10,11]. These cell–cell and cell–matrix interactions regulate tumor 
growth, angiogenesis, aggression, invasion, and metastasis (Fig. 1) [12,13]. In the early 
stages of cancer, tumor cells undergo certain alterations (a process called immunoediting) to 
initiate signaling pathways that inactivate the immune system to prevent their elimination 
from the body [14,15]. Such alterations allow cancer cells to avoid the body’s immune 
response and grow abnormally to form a large tumor mass.
During immunotherapy, the native immune system is reactivated by administration of 
peripheral blood lymphocytes or immune modulatory drugs [16]. Various immunotherapy 
drugs have been introduced in the past to treat cancer patients, but many of them have not 
exhibited a good response during phase I/II clinical trials [17]. For example, the first 
immunotherapy (Sipuleucel-T, Provenge) for castration-resistant prostate cancer patients 
approved by United States Food and Drug Administration (FDA) prolonged the survival of 
cancer patients by only a couple of months as compared to standard drugs and placebo 
controls [18]. Furthermore, in many clinical trials, drug testing is also hampered by the 
limited enrollment of cancer patients [19]. Such drawbacks limit the development of new 
drugs for cancer patients.
Two-dimensional (2-D) in vitro cancer models and small in vivo animal models are used 
conventionally for drug testing and screening [20,21]. However, because of the difficulty in 
recapitulating the natural tumor microenvironment in 2-D culture as well as the cost and 
issues associated with animal models, both approaches have become less attractive for 
routine drug testing. New three-dimensional (3-D) in vitro cancer models have emerged as 
an alternative approach to conventional methods and have shown the potential to recapitulate 
the natural microenvironment of tumors in a relatively simple and inexpensive way when 
compared to conventional methods [22–29]. In this article, we review the significance and 
limitations of different tumor models used in the literature for drug testing. We also discuss 
various approaches that are currently available for generating 3-D tumor models such as 
spheroids, hanging drop, bio-printing, and magnetic levitation. In addition, we evaluate the 
effect of materials (e.g., basement membrane matrix, hydrogels, and scaffolds) and physical 
parameters (e.g., stiffness, morphology, flow, and shear stress) on the growth, invasiveness, 
differentiation, and regulation of biomarker expression of cancer cells. Finally, we highlight 
future directions for 3-D cancer models toward applications in anti-cancer drug 
development.
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Strengths and limitations of 2-D vs. 3-D tumor models
Cancer cells are routinely cultured on 2-D plastic substrata in the pharmaceutical industry 
[30]. In 2-D tumor models, cancer cells are grown as a monolayer and do not mimic the 
native tumor environment [21,31]. The cells sit on a flat 2-D surface with almost half of the 
cell’s surface directly bound to plastic substrata. Cancer cells grown on a 2-D surface lose 
certain signaling pathways that are important in defining cell’s natural response in terms of 
growth, metabolism, and differentiation [31–34]. In one study, human breast tumor cell line 
(T4-2) derived from phenotypically normal cells (HMT-3522) cultured on 3-D basement 
model underwent concomitant down-regulation of epidermal growth factor receptor (EGFR) 
and β1-integrin when the cells were treated with antibody mediated inhibition factors [35]. 
The modulation of these receptors in 3-D tumor model led to growth arrest and finally 
reversion of malignant behavior of T4-2 cancer cells to normal breast tissue morphogenesis 
[35]. On the other hand, when T4-2 cancer cells were cultured on 2-D substrata and treated 
with antibody inhibition factors, no down-regulation and growth arrest were noticed [35]. In 
another report, a human breast cancer cell line (MCF-7) and its multidrug resistance variant 
(MDR-MCF-7) cells were cultured using 3-D spheroid and 2-D monolayer methods [36]. 
Both types of cancer cells showed reduced proliferation in 3-D culture as compared to 2-D 
monolayer culture. The cultured cancer cells were also treated with the anti-cancer drug 
doxorubicin. It was reported that MCF-7 cancer cells grown in the 3-D model had reduced 
sensitivity to doxorubicin as compared to 2-D cultures [36]. The MDR-MCF-7 cancer cells 
showed no response to drug treatment when cultured in a 3-D model. The invasive potential 
of MDR-MCF-7 cells was also increased when cultured in a 3-D model. Further, in the case 
of solid tumor, cancer cells are hypoxic at the center because of limited blood and oxygen 
supply [37,38]. This phenomenon cannot be mimicked in a 2-D culture model as cells grow 
in a single layer and every cell has continuous supply of oxygen and nutrients. These 
findings clearly pointed out that ECM composition and cell–matrix interactions play a vital 
role in cancer cell growth, metabolism, and invasiveness, and the complexity of the tumor 
microenvironment cannot be recapitulated in 2-D cancer cell culture models. Limitations of 
2-D tumor models were also highlighted by other reviews in the field [39–41].
Strengths and limitations of animal models of human tumors (xenografts)
Xenograft animal models of human tumors are widely used as in vivo tumor models for 
studying cancer metastasis and drug screening [42,43]. In this model, cancer cells are 
subcutaneously injected into immunocompromised mice and allowed to grow for a couple of 
weeks. It has been reported that small cancerous tissues implanted in respective organs 
(orthotopic) of mice were used to study the invasive and metastatic properties of cancer cells 
[42]. The cancer cells grow, because the immunocompromised mice do not generate 
sufficient immune response to the xenograft of human cells. On the other hand, the xenograft 
model does not fully mimic the natural response of the human body [44], as the 
immunocompromised mice lack some growth factors such as interleukin-8 (IL-8) that are 
secreted in humans by immune cells. In the case of ovarian cancer, the mouse omentum is 
located close to the pancreas having different histological appearance as compared to human 
omentum [45]. These findings may partially explain why only 27% of drugs with good 
efficiency in animal models show no sensitivity during phase II clinical trials [46,47]. This 
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clearly indicates that alternative 3-D tumor models are required to better mimic the body’s 
natural response and to allow direct observation of the tumor during the course of the 
treatment.
Technologies to develop 3-D cultures and spheroids
Tumor cells growing in conventional monolayer 2-D in vitro systems have limited ability to 
mimic the in vivo cell–cell and cell–matrix interactions [48,49]. However, when tumor cells 
are cultured in a 3-D in vitro system, they support each other and behave in a way that is 
similar to the in vivo system (e.g., adhesion, motility, invasiveness and metastasis) [50–53]. 
In addition, in 3-D culture endothelial and stromal cells can be mixed in a particular 
proportion allowing them to mimic cellular organization in human tumors, and exchange 
growth factors and other extracellular matrix proteins [54,55]. In the following sections, we 
discuss various tools currently available to develop 3-D cancer models along with material 
prospects. The strengths and limitations of each method are highlighted in the respective 
paragraphs.
Spheroids and hanging drops
Spheroid aggregation of cells is one of the easiest ways to culture tumor cells in 3-D [56]. 
Because of self-assembly, reproducibility, and similarity to native tissues, spheroid 
formation for 3-D tumor culture has become a well-characterized model [56–59]. Production 
efficiency, spheroid size uniformity, influence of cellular physiology, and suitability for 
subsequent application are the general criteria for selecting the spheroid production method 
[60]. Because of its simplicity, the hanging drop technique emerged among various other 
techniques (e.g., liquid-overlay and gyratory rotation methods) to promote 3-D spheroid 
formation through natural aggregation [61]. The gravity in the pipetted droplets concentrates 
cells at the liquid-air interface to generate spheroids when the lid is inverted. Although this 
method is simple and inexpensive to generate spheroids, high throughput and control of 
droplet size and uniformity are present challenges. Recently, microfluidic chips have been 
described to overcome the limitations of the conventional techniques; however, these 
spheroid-on-chips suffer from the difficulty of providing long-term cultures [62–66]. 
Additionally, the liquid handling robots, which perform high throughput screening are 
incompatible with the microfluidic approach [57]. A high-throughput 384 well hanging drop 
array was developed for spheroid formation, culture, and drug screening that is compatible 
with the existing liquid handing robots (Fig. 2a) [57,67]. By utilizing this approach, the 
researchers showed that the 3-D culture models of human epithelial carcinoma cells were 
more resistant (75% viability after 96 h) to anticancer drug 5-fluorouracil than cells 
evaluated in 2-D culture (5% viability after 96 h). However, 3-D cultured cells were less 
resistant (40%, compared with 75% in 2-D) to the hypoxia activated tirapazamine drug, 
where the active oxygen consumption and limited oxygen diffusion created a hypoxic and 
necrotic core, which synergized with the effect of the drug [57].
Despite its simplicity, the hanging drop technique based on manual pipetting is time-
consuming and labor-intensive. The results vary between operators because of their 
technique and skill level. These technical limitations are also responsible for increased 
Asghar et al. Page 4
Mater Today (Kidlington). Author manuscript; available in PMC 2017 April 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
mechanical stress on the cells, which affect the 3-D geometry of the droplet and 3-D 
structure of the culture system [68]. Furthermore, the non-homogeneous spreading of the 
droplet during manual pipetting leads to non-uniform cell densities in the droplet. In an 
attempt to overcome these challenges, a reproducible, efficient, and scalable method was 
developed to generate a more controllable uniform-sized 3-D culture by integrating the 
existing hanging-drop method with bio-printing technology (Fig. 2b) [68]. This combined 
approach is simple, robust, and reproducible, utilizing a valve-based bio-printing 
methodology that can generate 160 droplets per second. Generating an equal number of 
droplets (160 droplets) by the conventional manual pipetting method would take up to 10 
min [68].
3-D bio-printing of cancer cells
In recent years, there has been increasing interest in integrating bio-printing technologies 
with stem cells, cell bio-preservation, and cancer research [69–81]. Cell printing is an 
emerging approach for 3-D cancer cell patterning, which provides control over spatial and 
temporal distribution of cell seeding [81–84]. In a recent study, a high-throughput automated 
bio-printing approach was utilized to pattern a 3-D co-culture model of human ovarian 
cancer cells and fibroblasts-encapsulated droplets with high cell viability (Fig. 3a) [70]. This 
approach provided reproducible control over spatial distance between cell types (i.e., cancer 
and stromal cells). Although other bio-printing methods (e.g., inkjet and laser printing) have 
been developed to control cell seeding in 2-D and 3-D models, these methods have some 
limitations (Fig. 3b and c) [78,85,86]. For successful delivery of bio-fluids, inkjet and laser 
technologies require certain design parameters to avoid damaging of pressure- and heat-
sensitive fluids [69,87]. This is crucial when printing live cells, as they do not tolerate high 
temperature and stress [69,88,89]. Although inkjet printers are simple in design and can 
print various types of materials, it is difficult to achieve the directionality with the traditional 
inkjet devices as the ejection directionality is limited by the geometry of the nozzle [69]. As 
an alternative, an acoustic picoliter droplet ejector was designed for precise cell 
encapsulation in bio-fluids with high viability, and high directionality via an open-pool 
nozzleless ejection system actuated by an acoustic field [90,91]. The acoustic ejector is 
simple and performs reliably without generating excessive heat and pressure-sensitive fluids 
[69,90,91]. In summary, the bio-printing technology is an attractive approach for various 
applications in 3-D tumor models generation, tissue engineering, and regenerative medicine.
Cell assembly with and without magnetic nanoparticles
Utilization of non-invasive approaches such as magnetic levitation to assemble 3-D complex 
structures has recently been demonstrated [92–97]. Several fields including 3-D cell 
culturing have adapted the magnetically driven platforms [98–103]. An ability to create 3-D 
tumor spheroids that mimic in vivo tumors by utilizing a magnetic cell levitation method has 
been demonstrated [104]. Magnetic iron oxide (Fe3O4)-encapsulated poly(lactic-co-
glycolide)(PLGA) micro-particles or poly(L-lactic acid)-b-poly (ethylene glycol)-folate 
[PLLA-b-PEG-folate] nanoparticles were utilized as substrates for 3-D tumor cell culture. 
The technique is based on the use of a simple, adaptable magnetic levitation of Fe3O4 nano-/
micro-particles to achieve 3-D tumor structure (Fig. 4a). A similar methodology was 
adopted to generate 3-D tissue culture of human glioblastoma cells (Fig. 4b–d) [101]. The 3-
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D cultured glioblastoma cells showed similar morphological and molecular characteristics to 
the orthotopic human xenografts from immunodeficient mice. The N-cadherin (a 
transmembrane protein mediating cell–cell contact) was expressed in the membrane, 
cytoplasm, and cell junctions, whereas in 2-D cultures the biomarker was dispersed in the 
nucleus and cytoplasm. The study utilized the magnetic levitation of cells in the presence of 
a hydrogel enclosing gold nanoparticles, magnetic iron oxide nano-particles, and 
filamentous bacteriophages during photo-crosslinking [93]. Although the applications of 
these magnetic nanoparticles (MNPs) loaded into the cell-encapsulated hydrogels (M-gel) 
have been utilized in tissue engineering, the possible interaction between the MNPs and 
encapsulated cellscan potentially affect their viability and functionality [93,94]. These 
MNPs can be released from biodegradable hydrogels in cultures overtime [105]. In 
alternating current magnetic field,the magnetic hyperthermia could affect the cells and lead 
to disassembly of the hydrogel as a result of accumulation of thermal energy inside the gels 
[95,106]. On other hand, in permanent magnetic field these adverse effects are not observed 
[95]. Although the FDA has approved the use of MNPs in several applications (e.g., imaging 
agent), further nanotoxicological studies would be vital for future applications including 3-D 
cell culture, drug testing, and regenerative medicine [93,107]. Recently, living soft materials 
were assembled by paramagnetic levitation-based approach (Fig. 5a and b) [95,108,109]. 
This approach manipulated cell seeded units (microgels and microbeads) in paramagnetic 
gadolinium-based medium for bottom-up tissue engineering. The microgels and microbeads 
were assembled in magnetic fields by their paramagnetic properties, without integrating 
them with other magnetic components (e.g., magnetic nanoparticles) [95,109]. This method 
is cost effective and as it does not require the expensive and potentially toxic MNPs. 
Furthermore, hydrogels can be assembled by non-magnetic methods using a micro-robotic 
system as recently demonstrated [96]. These untethered micro-robots are actuated by an 
external magnetic field and their motion can be controlled precisely to assemble 2-D and 3-
D hydrogels encapsulating various types of cells (Fig. 5c). Alternatively, Faraday waves 
have been employed for liquid-based templated sound-based assembly of hydrogels and 
cells [110]. Topography of the liquid surface established by standing waves serves as a 
template for directed assembly of a large number of hydrogels quickly (in about 5 s) into 
diverse sets of ordered and symmetric structures (Fig. 5d). The assembled hydrogels can be 
immobilized by chemical- and photo-crosslinking for stable assembly. These hydrogel and 
cell assembly methodologies provide a new way of engineering 3-D constructs and present 
broad potential applications in regenerative medicine, drug screening, and experimental 
biology.
Basement membrane extract from mouse sarcoma
The basement membrane is a part of the ECM structure. It is composed of various proteins 
such as laminin, fibronectin, and collagen IV that are important for tissue growth and 
organization [111,112]. The basement membrane extract is routinely obtained from cancer 
cell cultures of mouse sarcoma (Engelbreth-Holm-Swam, EHS) and used for various 
applications in tissue engineering. The extracted EHS membrane extract is commercially 
available from different companies such as BD Matrigel™ and Trevigne Cultrex1. These 
membrane extracts resemble the natural tumor microenvironment and contain laminin 
(60%), collagen IV (30%), and entactin (8%). Various growth factors and hormones 
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including matrix metalloproteinase (MMP) enzymes that remodel ECM and promote cancer 
cell proliferation are also present [111,112]. When lung cancer cells were mixed in Matrigel 
and injected subcutaneously in an animal model, they rapidly formed a bigger tumor mass 
compared to injected cancer cells without Matrigel [113]. Other cancer cell lines such as 
A253 and B16F10 have also shown enhancement of cell growth rates (~5–10 times) when 
co-injected with Matrigel [113]. Furthermore, multicellular cultures can be obtained easily 
by mixing different cell types together with Matrigel. In one study, breast cancer cells and 
fibroblasts were mixed with Matrigel and co-cultured [114]. The grown tumor showed a 
more invasive response as fibroblast cells released MMP enzymes that reorganized the ECM 
[114]. Although the basement membrane extract is a powerful model to study the tumor 
behavior, it has a few limitations. Matrigel does not have high portions of collagen-I and 
hyaluronan that are usually present in high proportions in in vivo tumor microenvironments. 
These proteins play an important structural role in organizing tissue architecture. In the 
absence of these proteins, natural in vivo response of cancer cells may not be recapitulated 
in Matrigel [115]. The presence of unknown amount of other growth factors and proteins is 
another limitation associated with the use of Matrigel. The composition of Matrigel has 
batch to batch differences that have uncontrolled effects on cancer cell behavior [116]. As 
the composition of Matrigel cannot be controlled, the effect of a single hormone or growth 
factor on cancer cell behavior cannot be studied specifically. Despite these limitations, 
Matrigel is a natural gelatinous protein from mouse sarcoma cells and has found potential 
applications in the field of tumor growth and drug screening.
Hydrogel cellular scaffolds
Hydrogels are a crosslinked network of polymers and can absorb up to 99% of water 
because of their highly porous structure. Hydrogels are widely used in many cell culture and 
tissue engineering applications because of their high resemblance to physical structures of 
natural ECM [117,118]. Various natural and synthetic polymers are used for hydrogel 
synthesis. Examples of naturally occurring polymers and proteins used for hydrogel 
formations are collagen, hyaluronic acid, fibrin, silk protein, fibronectin, alginate, agarose, 
and chitosan [10,119–122]. Many of these natural substances are obtained from the 
mammalian ECM (hyaluronic acid, collagen and fibrin), whereas silk protein is obtained 
from silkworm [117,123]. Hydrogels made of natural polymers have been utilized in many 
cancer cell growth and proliferation studies [124,125]. In one study, three different 
populations of cells (luminal cells/MCF-7, myoepithelial cells and fibroblasts/tumor 
associated fibroblast) of breast tissue origin were mixed in a collagen hydrogel and allowed 
to grow over a period of 1 week [125]. Dual-cell co-units were formed with myoepithelial 
cells surrounding luminal cells (Fig. 6a(ii)). Cancer cells (MCF-7) and myoepithelial co-
units both had disrupted basement membranes resembling in vivo ductal carcinoma in situ 
(DCIS), differentiating them from normal cell co-units [125]. Normal fibroblast cells had no 
effect on co-unit organization when cultured with luminal and myoepithelial cells, whereas 
the tumor associated fibroblast cells disrupted the co-units organization by releasing MMP 
enzymes (Fig. 6). Besides natural hydrogels, many synthetic hydrogels are also introduced 
in tissue engineering including Poly(hydroxyethyl methacrylate) (PHEMA), Poly(vinyl 
alcohol) (PVA), Poly(ethylene glycol) (PEG), Poly(acrylic acid) (PAA), Poly(methacrylic 
acid) (PMMA), and Poly(acrylamide) (PAAm) [117]. Synthetic hydrogels are also 
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commercially available such as self-assembling peptide hydrogel (RAD16-I) matrix (BD™ 
PuraMatrix™). Using hydro-gels, we can have a better control over the quantity of ECM 
proteins and growth factors, whereas basement membrane extract has non-quantified 
composition [116,126,127]. Ovarian cancer cells organized into an acinar shape when mixed 
with PuraMatrix hydrogel. The acinar shape resembled the in vivo cancer metastatic nodules 
[128]. PuraMatrix hydrogel was also functionalized with various motifs such as collagen, 
laminin and fibronectin. The addition of these functional motifs has been shown to increase 
the cell survival and attachment [129,130].
Polymeric scaffolds
Polymeric scaffolds are microporous structures with highly interconnected architecture 
similar to hydrogels. The main difference between polymeric scaffolds and hydrogels is that 
polymeric scaffolds are synthesized before cell seeding, whereas in hydrogel cells can be 
mixed with polymers before hydrogel formation [94,131]. Polymeric scaffolds are 
synthesized from natural (Collagen, Chitosan, Alginate) and synthetic polymers including 
PEG, polylactide (PLA), poly(lactide-co-glycolide) (PLG), polyglycolide (PGA), 
polystyrene, and poly(lactic-co-glycolic acid) (PLGA) [10,132–137]. Various polymeric 
scaffolds are commercially available in synthetic, non-degradable polystyrene (Alvetex by 
Reinnervate [138], 3-D insert PS by 3-D Biotek [139]) and natural degradable alginate forms 
(AlgiMatrix 3-D by Invitrogen) [140]. Polystyrene culture plates are routinely used for 2-D 
cell culture in laboratories. 3-D polystyrene based scaffold can be synthesized to get benefits 
of 3-D topography. In one report, lymph-node-derived HBL-2 cells showed increased growth 
rates when cultured in 3-D polystyrene scaffold as compared to 2-D polystyrene plates 
[139]. In another report, PLG synthetic scaffolds were used to study the behavior of tumor 
cells on these scaffolds. Oral squamous cell carcinoma (OSCC-3) and mouse Lewis Lung 
Carcinoma (LLC) cells were cultured on 3-D PLG scaffolds and 2-D culture plates then 
implanted into immunocompromised and immunocompe-tent mice, respectively [37]. The 
cancer cell growth was analyzed after 3 weeks. The OSCC-3 and LLC cancer cells pre-
cultured on 3-D PLG scaffolds developed into larger tumor mass as compared to cells pre-
cultured on 2-D plates (Fig. 7). The tumor cells pre-cultured on 3-D PLG scaffolds produced 
more angiogenic factors including the vascular endothelial growth factor (VEGF), basic 
fibroblast growth factor (bFGF), and IL-8 [37]. The increased level of angiogenic factors 
resulted in generation of more blood vasculature. 3-D porous chitosan-alginate (CA) based 
natural scaffold was synthesized for studying the prostate cancer cell–lymphocyte 
interactions [2]. Three different prostate cancer (PCa) cell lines (LNCaP, C4-2 and C4-2B) 
were cultured on 2-D culture plates, 3-D CA scaffolds, and in Matrigel for 15 days [2]. The 
cancer cells cultured on 2-D plates formed a flat layer of cells (Fig. 8). The Matrigel culture 
produced tumor spheroids, but the cells attached to the bottom plate surface formed flat and 
elongated shapes. All three cancer cell lines formed perfect spheres in the pores of 3-D CA 
scaffolds resembling the morphology of in vivo tumor mass (Fig. 8) [2]. These scaffolds also 
sustained the cancer cell growth for a longer period of time (55 days) without degradation, 
whereas Matrigel became highly degraded after one week. However, many polymeric 
synthetic scaffolds do not show good cellular attachment because of material properties such 
as type and degree of porosity. Enhanced cellular attachment is achieved by incorporating 
hydrophilic polymers (e.g., PVA and chitosan) into such synthetic scaffolds [141]. 
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Incorporating ECM components in such synthetic scaffolds would enhance the cellular 
response in vivo.
Dynamic tumor models based on microfluidics
Microfluidic technologies allow precise control on small volumes of fluid inside channels 
and find numerous applications in disease diagnostics and medicine [142–147]. Various 
dynamic platforms based on microfluidic technologies have also been developed to model 
tumor microenvironment in vitro [148–151]. Microfluidic platforms allow a continuous 
supply of nutrients to growing cells, and have the ability to analyze the effects of shear stress 
on tumor cells [152,153]. In one study, a microfluidic platform was developed to study the 
effect of anti-cancer drug (Tegafur) on colon cancer cells while establishing multi-organ 
interactions [154]. The microfluidic platform was composed of three separate cell-hydrogel 
chambers containing colon cancer cells, hepatoma cells, and myeloblasts representing 
cancer, liver, and marrow, respectively. These cell-hydrogel chambers were connected with 
microfluidic channels mimicking blood flow. Using this device, researchers have 
successfully shown the metabolism of Tegafur in the liver chamber, followed by death of 
cancer cells by metabolic products. In another report, a dynamic microfluidic device was 
developed to analyze the albumin release from carcinoma cells embedded into peptide 
hydrogels [155]. The device also enabled chemotaxis studies by producing a gradient profile 
across carcinoma cells. Dynamic tumor platforms can be integrated with live-cell 
fluorescence microscopy to study the minute interactions between cancer and other cells 
such as endothelial cells forming blood vessels [156]. To study these interactions, a 
microfluidic platform was recently developed, which consists of an artificial blood vessel 
(lined with human umbilical vein endothelial cells) surrounded by breast cancer cells in 
ECM. Using this platform, scientists have shown the precise movement of breast cancer 
cells toward a vessel by forming a tunnel in ECM. Hence, these dynamic platforms can 
potentially be used in drug screening mimicking physiological environments, while 
reproducing multi-organ interactions.
Systems to model the effects of physical factors
The chemical, mechanical, and structural stimuli to mammalian cells in 3-D 
microenvironments in the human body change through the invasion and progression of a 
disease [157–160]. Through the course of cancer metastasis, cancer cells exfoliate from the 
primary solid tumor and enter the circulatory system of the patient to find an appropriate 
remote site to create a secondary tumor [161,162]. During this process, invasive cancer cells 
have to migrate through tiny pores in the 3-D ECM microenvironment [163–165]. Therefore, 
investigating the physical interaction between the invasive cancer cells and their 3-D 
microenvironments as well as their cellular response physical factors (i.e., ECM stiffness, 
flow, and shear stress) can lead to a better understanding of cancer metastasis mechanisms 
[165–169]. For instance, cancer cell migration has been investigated in spatially 3-D 
gradient microenvironments using polydimethylsiloxane (PDMS) tapered microchannels 
that connect a wide microchannel (4 μm × 10 μm) to a narrow microchannel (15 μm × 10 
μm). This study revealed how cancer cells migrated from a more confined environment 
(narrow channels) to a region with greater amounts of freedom (wide channels). Highly 
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metastatic breast cancer cells (MDA-MB-231) migrated through the tiny microchannels in a 
PDMS device, whereas non-metastatic breast cancer cells (MCF-10A) showed less 
invasiveness, as they could not migrate through the narrow channels [165].
Cancer cell response to matrix stiffness
Matrix stiffness is another important parameter in studying the cellular response of cancer 
cells in 3-D microenvironment [170]. The matrix stiffness of different body organs can be 
quantified by Young’s modulus (E) that can be soft as brain tissue (250–500 Pa) or rigid as 
bone (1–25 GPa) [159,171]. Cellular mechanical response in these microenvironments with 
different degrees of ECM mechanical stiffness is different. Matrix stiffness of solid tumors 
changes during the course of cancer metastasis and progression [157,172]. For instance, 
breast tumor has shown a stiffer microenvironment (4000 Pa) compared to the healthy breast 
tissue (200 Pa) [157]. One of the most popular and effective protein hydrogels that has been 
used to investigate cancer cell response to 3-D matrixes with different stiffness is collagen 
hydrogels [157,159,173]. The stromal collagen deposition and crosslinking can define the 
stiffness of the tumor microenvironment and consequently can alter the cancer cell migration 
through the ECM [173]. In one report, a substrate with varying stiffness was synthesized 
using polyacrylamide hydrogel and cells migrated from a soft substrate to a stiffer substrate 
[174]. This study showed that the cells grown on stiffer substrates had longer contact 
lengths. In another investigation, metastatic cancer cells were characterized by measuring 
the traction forces applied to 2-D and 3-D matrixes via cancer cells on these substrates 
[175]. Breast, lung, and prostate cancer cells showed significantly stronger traction forces on 
the substrate at the late stage of the cancer disease compared to the normal healthy cells. 
Further, these results showed that cancer cells created stronger contractile forces on matrixes 
with higher stiffness. The degrees of the traction and contraction forces generated by cancer 
cells are determined by the chemical and mechanical properties of tumor microenvironment 
[8,175].
Cellular response to fluid shear stress
In addition to the matrix stiffness, fluid shear stress in the 3-D microenvironment inside the 
ECM is another critical extracellular stimulus that modulates MMP genes [176]. The ECM 
structure surrounding the solid tumor is degraded during the very first stage of metastasis 
because of matrix MMPs [177–179]. In this case, shear forces on the cancer cells exfoliating 
from the primary tumor can potentially change the mechanical response and migration of 
invasive cancer cells entering into the circulatory system [176]. To verify this phenomenon, 
a recent study has investigated the effect of shear stresson cell migration [179]. Inthisstudy, 
fluid flow and shear stress on the cancer cells changed the migratory response of the cancer 
cells by reducingtheir motility because of changing the level of MMP expression in the 
microenvironment [179]. The results explained why the glioma cells in vitro had different 
invasiveness compared to in vivo [179]. In another instance, researchers have investigated 
the role of fluidic shear forces in cancer metastatic biology in a micro-fluidic platform using 
3-D ovarian cancer nodules [28]. They observed that the fluidic shear forces induce 
aggressive tumor phenotype by posttranslational up-regulation of EGFR and vimentin, and 
down-regulation of E-cadherin protein expression [28].
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Cancer cell response to host immune modulatory effect
The development, growth, invasion, and treatment of cancers are clearly influenced by the 
interaction of tumor cells with immune system. Culturing these cells in 2-D has enabled 
discovery of new drugs and has allowed for a better understanding of cancer patho-
physiology. However, these 2-D cultures are still unable to recapitulate the 3-D tumor 
microenvironment, resulting in wide discrepancies between immunotherapy data obtained 
from in vitro experiments and clinical trials [180,181]. In addition, although animal models 
have been useful in evaluating tumorigenic potential of cancer cells, these models lack the 
same tumor and immune system interactions present in humans, because tumor cells in these 
models are cultured in complete or partial absence of immune cells and immune modulatory 
chemical factors such as cytokines, and in the presence of the animal stromal cells and 
matrix [180,182,183]. Therefore, modulating the tumor and immune system interactions in 
3-D cultures can be of great importance for successfully evaluating cancer immunotherapy 
and drug screening. Recent studies have integrated immune cells in 3-D culture to study 
their association with tumors, aiming to develop better in vitro models for drug testing and 
experimental cancer biology [184,185]. For instance, macrophages (which are usually 
recruited by solid tumors during their progression) were integrated into a collagen-based 3-D 
co-culture system of squamous cell carcinoma (SCCs) [185]. The study demonstrated that 
M2 polarized populations of macrophages have tumor-promoting effects. This approach, 
which established a complex human 3-D model system for skin SCCs, has the potential to 
explore the activation of macrophages in human systems during cancer progression. In a 
similar study, melanoma cells cultured in spheroids showed immunomodulator functions in 
addition to inhibition of mitogen-dependent T-lymphocyte activation and proliferation, 
which suggests an important role of spheroids in evading immune surveillance [184]. This 
approach provides a useful model to study the aggressiveness of certain malignancies and 
can be utilized to investigate the poor responses of malignancies to various immunotherapy 
drug treatments. Furthermore, modulating the tumor microenvironment to favor the presence 
of pro-inflammatory cytokines has been shown to enhance the immune response by 
promoting immune cell migration and activation [186]. For example, the expression of 
chemokine ligand 21 (CCL21) and interferon gamma (IFNγ) in a breast cancer 3-D model 
demonstrated the ability to enhance T cell recruitment and activation in the tumor [187]. 
Overall, the ability of a 3-D culture system with the addition of immune cells or immune 
factors to better mimic tumor microenvironments would potentially develop new platforms 
for cancer therapy.
Imaging 3-D cultures in living animals
It is clear from the literature that 3-D cultures are able to control and produce precise 
microenvironment that is more similar to human tissues. The microenvironment can also be 
modified by the use of various biomaterials with specific properties as discussed in previous 
sections. The animal models implanted with xenograft of cells grown in 3-D scaffolds with 
human tissue microenvironment can add another dimension by providing a more similar in 
vivo model system to study human cancers for drug testing, evaluating metastasis and 
invasive profile of cancer cells, and also in various cell therapy studies for cardiac and islet 
transplantation. Currently, noninvasive small animal imaging provides the advantage of 
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monitoring various properties of cells implanted within scaffolds in intact live animals over 
time without sacrificing them. Bioluminescence imaging, fluorescence imaging, X-ray 
assisted computer tomography imaging (CT), and magnetic resonance imaging (MRI) offers 
imaging cells implanted in 3-D scaffolds with or without pre-labeling. Adipose-derived 
progenitor cells (ADPC) dually labeled with bioluminescent (Firefly luciferase) and 
fluorescent (GFP) reporter genes cultured in a combination of porous elastomeric membrane 
and peptide hydrogel, were evaluated as a bio-implant for cardiac regeneration in a mouse 
model of myocardial infarction [188]. As ADPC expresses reporter genes, the viability and 
function of cells can be monitored by imaging and can also be compared with the 
improvements in cardiac function. The results of this study showed a well-adapted bioactive 
implant to the heart, and developed fully functional vessels across the myocardium and 
bioactive implant interface. The results also achieved significant improvement in the cardiac 
function, as revealed by echocardiography. Similarly, in another study various 3-D culture 
systems, such as Porous Polycaprolactone Scaffold (Kiyatec), Hyaluronic Acid Gel 
(Celenys), Magnetic Levitation Bioassembler (n3D Biosciences), and UV Cross-linked 
Poly-ethylene Glycol Hydrogel were developed to mimic human in vivo condition similar to 
ECM, and study the conditions using cells pre-labeled to express bacterial luciferase (lux 
gene) by bioluminescence imaging [189]. This study tested the system under various 
conditions, such as growth temperature, time period and antibiotic treatment response, and 
the results showed the bioluminescence imaging can feasibly differentiate the response of 
cells in a 3-D culture system under various conditions.
MRI is a high resolution imaging technique routinely used for various diagnostic 
applications including cancer. MRI is used in combination with various contrast agents for 
cell tracking in stem cells studies. Adipose Derived Stem Cells (ADSCs) isolated from 
human tissues labeled with Ultrasmall Super Paramagnetic Iron Oxide (USPIO) particles 
seeded within a 3-D porous polysaccha-ride-scaffold were subcutaneously implanted in 
animals for tissue engineering and monitored by MRI over time [190]. The USPIO labeling 
of cells did not affect the viability and differentiation potential of ADSCs. The in vivo 
imaging in animals showed the presence of viable cells even 28 days after implantation and 
cells migrated and colonized around the scaffold. Similarly, in another study, three different 
structures with tunable architectures prepared from naturally occurring polysaccharides were 
explored as scaffolds for mesenchymal stem cell (MSC) culture using a 1.5T high resolution 
MRI. The study used anionic citrate coated iron oxide nanoparticles as MR contrast agents 
to label MSCs. In vivo imaging of MSC in 3-D scaffolds clearly detected the architecture of 
the scaffolds [191]. Although the development of 3-D culture system for various 
applications has been widely studied [192], the feasibility of imaging 3-D scaffolds in 
animal models for long-term functional evaluations is still limited.
Future research directions and concluding remarks
3-D cancer models recapitulate native tumor environment compared to monolayer cultures 
and standardization and automation of 3-D tumor models are needed for broad applications. 
Although hundreds of thousands of spheroids can be synthesized using bio-printing and 
hanging drop methods, there are concerns about production efficiency and spheroid size 
uniformity. Variations in spheroid size affect the uniform diffusion of nutrients inside the 
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core and, hence uneven cell growth was observed in individual spheroids [193]. In the case 
of scaffold based 3-D models, the nature of scaffold material affects the absorption and 
adhesion of the drugs that are being tested [194]. The scaffold and materials should be 
carefully selected based on the nature of screening drugs and their interactions with various 
materials [195,196]. Although 3-D tumor models allow co-culture of various cell types 
mimicking tumor environment, an exhaustive set of experiments need to be designed to 
analyze the effect of each cell population on others. Various cell types will require different 
culture conditions; one culture medium may not be effective for all cell types. The 
requirement of maintaining specific growth conditions for various cell types inside a 3-D 
tumor model may require complex peripheral component design. The effect of ratio of a 
specific cell type to other cells in a co-culture environment should also be thoroughly 
explored and experiments should be performed to not only analyze commonly tested 
parameters such as cell growth and invasiveness, but genetic and epigenetic changes should 
be analyzed over a period of time. 3-D tumor models showing promising results during 
exhaustive cross-pharma validations could potentially be adopted by pharmaceutical 
industry.
3-D tumor models should be capable of automated readout and imaging [197]. The image 
analysis of cancer cells in 3-D cultures is often limited by autofluorescence of scaffold 
material such as collagenous scaffolds. Cancer cells encapsulated into 3-D tumor models 
need to be recovered for further biochemical and cell analysis. Methods are lacking for 
gentle recovery of growing cancer cells from non-degradable scaffolds such as polystyrene 
based synthetic scaffolds. Researchers have synthesized PLG based 3-D scaffolds that can 
be degraded enzymatically to release cultured cancer cells without affecting them [37]. In 
one recent report, a porous 3-D collagen-alginate scaffold was synthesized and degraded by 
the addition of ionic solution. The polyelectrolyte complex between alginate and collagen 
was disrupted by the ionic solution leading to degradation of 3-D scaffolds and release of 
cancer cells [2]. Similar methodologies should be adapted for other 3-D scaffold models. 
Although the scaffold-free 3-D tumor models are considered more compatible with 
automation, they have uncontrolled composition and batch-to-batch variation (basement 
membrane extract). One way to standardize the 3-D model composition is to allow the 
stromal cells to deposit their own basement membrane extract before cancer cells are further 
cultured [197]. Furthermore, the capability of co-culturing the patient’s own cancer, 
immune, and stromal cells to generate 3-D tumor models would truly personalize cancer 
therapy and create a new area in precision medicine. This approach would allow to develop a 
new line of effective and customized drugs that are targeting specifically the patient’s own 
cancer cells. In addition, this approach has the potential to minimize the side effects 
associated with drug screening using conventional drug testing methods. The future is 
promising for such approaches, where the patient’s life is prolonged and quality of their 
health is maintained.
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FIGURE 1. 
Methods and materials used to engineer 3-D cancer models. To generate 3-D cancer models 
various technologies are used including spheroids, bio-printing, and assembly. These 
technologies are implemented using numerous kinds of materials such as hydrogels, 
scaffolds, and basement membrane extracts. Controlling physical and chemical factors and 
mimicking the native microenvironment results in tumor responses such as cancer cell 
proliferation, aggression, and invasion.
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FIGURE 2. 
High throughput methods to generate spheroids through hanging drop approach. (a) (i) 
Actual image of the 384 hanging drop array plate highlighting the key features and 
specifications. (ii) Schematic of the hanging drop formation process in the array plate. Cell 
suspension is dispensed into the access hole to the bottom surface of the plate using pipette 
and within hours, individual cells start to aggregate and eventually form into a single 
spheroid after 1 day. (iii) Schematic showing the humidification chamber that was used to 
culture 3-D spheroids in the hanging drop array plate format. The 384 hanging drop array 
plate was sandwiched between a 96-well plate filled with distilled water. Reprinted by 
copyright permissions from [57,67]. (b) (i) Schematic of the embryonic body formation 
process using hanging drop with integrated bio-printing approach. This approach can be 
utilized to make 3-D cancer models. Droplets of cell-medium suspension were printed onto 
the lid of a Petri dish and were hung up for 24 h to allow for EB aggregation. The formed 
EBs were transferred to a 96-well plate for additional culture up to 96 h. (ii) Images of 
uniformed-sized EBs formed using bio-printing with various droplet sizes: 1, 4, 10, and 20 
μl. (iii) Fluorescent images of EBs after 96 h of culture. Reprinted by copyright permissions 
from [68].
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FIGURE 3. 
Schematic of bio-printing technologies. (a) Schematic of the valve-based bio-printing setup 
used to make a 3-D co-culture of human ovarian cancer cells and fibroblasts. (b) Thermal 
and piezoelectric ink-jet printing. The thermal technique heats the resistor and expands the 
air bubbles. The piezoelectric technique charges crystals that expand. (c) Schematic of the 
laser printing setup where laser is focused into a cell suspension, and the optical force 
produced because of the difference in refractive indexes moves the cells onto an acceptor 
substrate. The cell-gel solution is propelled forward as a deposit by the pressure of a laser-
induced vapor bubble (right).
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FIGURE 4. 
Magnetic Fe3O4 encapsulated PLGA microparticles and iron oxide-containing hydrogels. (a) 
(i) Schematic representation of magnetic Fe3O4-loaded PLGA microparticles that were used 
for 3-D tumor spheroid cultures. (ii) SEM image of Fe3O4-loaded PLGA microparticles. (iii) 
Optical image of a cluster of KB tumor cells and PLGA microparticles. (iv) Optical image of 
KB tumor cell clusters (indicated by a white arrow) attached on the surface of magnetic 
PLGA microparticles. Reprinted by copyright permissions from [104]. (b) Human 
glioblastoma cells (lower arrow) mixed with magnetic Fe3O4-loaded containing hydrogel 
held at the air–medium interface by a magnet. Scale bar, 5 mm. (c) Comparison of 2-D with 
3-D cell growth. Phase contrast (top row) and fluorescence (red, bottom row) images of 
levitated glioblastoma cells. The cells were monitored for 8 days. Scale bar, 200 mm. (d) 
Confrontation assay of magnetically levitated multicellular spheroids. (i) Bright-field and 
fluorescence images of human glioblastoma cells (green) and normal human astrocytes 
(red). The cells were cultured separately and then magnetically guided together. (ii) Images 
showing confrontation between human glioblastoma cells and normal astrocytes monitored 
for 10.5 days. Invasion of normal human astrocytes containing spheroid by human 
glioblastoma cells serves as a standard assay to analyze glioblastoma invasiveness. Scale bar, 
200 mm. Reprinted by copyright permissions from [101].
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FIGURE 5. 
(a) Fabrication and magnetic levitational soft living materials. Reprinted by copyright 
permissions from [108]. (i) Schematic of hydrogel and cell seeded microbead fabrication. 
(ii) Paramagnetic levitational self-assembly of soft components. (iii) Red and blue hydrogels 
assembled at different levels because of their polymer concentrations. (vi) 3T3 seeded 
microbeads were self-assembled with Paramagnetic levitation. The cross sections of the 
layers were obtained by cutting the assembled construct into two hemispheres. (b) 
Paramagnetic levitation assembly of MNP-free hydrogel. (i–iii) Various hydrogel 
assemblies. Hydrogels were labeled with FITC-dextran (green) and Rhodamine B. (red) 
indicating control over the assembled constructs. (iv) Merged fluorescent image of layer-by-
layer 3-D assembly. Multi-layer 3-D constructs were fabricated by stacking layers of 
hydrogels. (v) Celtic-shaped patterning chamber. Each well is a reservoir for red, blue, or 
green hydrogels. Images show linear shape assembly of hydrogels with red gel at the front, 
in the middle, and at the back. Scale bar is 1 mm. Reprinted by copyright permissions from 
[95]. (c) Micro-robotic assembly of hydrogels and cells. (i) Magnetic coil system used to 
actuate magnetic micro-robots remotely. These untethered magnetic micro-robot were used 
to arrange hydrogels driven by magnetic field. Scale bar, 1 mm. Fluorescence images of 
National Institutes of Health (NIH) 3T3 mouse embryonic fibroblast cell-encapsulating 
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hydrogels after the assembly of (ii) T-shape and (iii) square-shape constructs. Scale bar, 500 
μm. (iv) Fluorescence image of three-dimensional heterogeneous assembly of HUVEC, 3T3 
and cardiomyocyte encapsulating hydrogels. Scale bar, 500 μm. Reprinted by copyright 
permissions from [96]. (d) Liquid-based templated assembly by Faraday waves. (i) 
Schematic demonstration of liquid-based templated assembly by Faraday waves. Dynamic 
reconfiguration of the assembled structures is achieved by setting vibrational parameters. 
(fA, aA) and (fB, aB) are vibrational frequencies and accelerations for the formation of 
structures A and B, respectively. By tuning the initial chamber with (fA, aA) and (fB, aB), 
assembly of the structures A and B from dispersed floaters can be performed, as well as the 
reversible transitions between the structures. (ii) Assembly of GelMA hydrogel units (dark 
blue) into various structures. (iii) Assembly of size-varied hydrogel units. PEG hydrogel 
units (light blue) with sizes of 0.5, 1, and 2 mm were assembled into the same pattern. Scale 
bars: 4 mm. Reprinted by copyright permissions from [110].
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FIGURE 6. 
Influence of fibroblast on co-units formations in collagen hydrogel. Fibroblast cells (green), 
myoepithelial cells (red) and MCF-7 cancer cells (blue). (a) (i) showed cell organization at 
the day 1. (ii) Cell organization at day 7 showed the homing of myoepithelial cells around 
the cluster of MCF-7 cancer cells. The normal fibroblast cells were arranged around the co-
units and had no effect on co-unit formation. (iii) Low power image of co-units. (b) (i) and 
(ii) show the disruption of co-units once the tumor-associated fibroblast were added. (iii) 
Low power image of disrupted co-units. Reprinted by copyright permissions from [125]
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FIGURE 7. 
Cancer cells were cultured on 3-D PLG scaffolds and 2-D culture plates before implanting in 
mouse models. (a) Tumor mass grown in mouse model after preculture of OSCC-3 cells in 
3-D PLG scaffold (right) and 2-D culture plates (left). Tumor grown in 3-D model was of 
higher weight and volume. (b) Tumor mass grown in mouse model after preculture of mouse 
LLC cells in 3-D PLG scaffold (right) and 2-D culture plate (left). Scale bars are 5 mm in all 
images. Reprinted by permission from [37].
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FIGURE 8. 
Scanning electron microscope (SEM) images of the three cell lines of prostate cancer cells 
cultured in different models (2-D, Matrigel and Chitosan-Alginate (CA) 3-D model). (a) 
SEM images of LNCaP cancer cells. (b) SEM images of C4-2 cancer cells. (c) SEM images 
of C4-2B cancer cells. The 2-D culture formed flat cell sheets whereas Matrigel and CA 3-D 
cultures formed spheroids mimicking in vivo tumor growth. Scale bars are 40 μm. Reprinted 
by copyright permissions from [2].
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